Physician profile
Barbara Einhorn
NPI 1376576462
$15,012.20
in general payments reported to CMS, 2019-2025
23 companies · $988 in 2025
The $988 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $525 · 2021: $474 · 2022: $597 · 2023: $4,533 · 2024: $7,247 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,820 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,751.37 |
| Food and Beverage | $1,820.11 |
| Education | $196.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,064.01 | 2019-2025 | |
| Janssen Biotech, INC. | $518.20 | 2019-2025 | Tremfya |
| Incyte Corporation | $476.78 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $332.08 | 2019-2024 | Ilumya |
| Amgen INC. | $207.09 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $184.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.26 | 2022-2024 | Sotyktu |
| Allergan, INC. | $143.33 | 2019-2022 | |
| Pfizer INC. | $132.04 | 2024-2025 | |
| Lilly USA, LLC | $112.93 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $111.83 | 2024-2025 | Daxxify |
| Biofrontera INC. | $93.37 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $80.14 | 2019-2024 | Bimzelx |
| Galderma Laboratories, L.P. | $68.85 | 2019-2024 | |
| Genentech USA, INC. | $61.94 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $58.08 | 2020-2022 | |
| Organon LLC | $45.59 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.15 | 2019-2023 | Libtayo |
| Leo Pharma INC. | $34.71 | 2023-2024 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $28.11 | 2019-2022 | |
| Celgene Corporation | $24.28 | 2019 | |
| Smith+Nephew, INC. | $23.65 | 2022 | |
| Arcutis Biotherapeutics, INC. | $15.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Einhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.